Contingency table of the original local diagnosis vs final study diagnosis
| Original local diagnosis . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | Total . | |
| MDS | 193 | 12 | 8 | 3 | 1 | 7 | 40 | 264 |
| MDS/MPN overlap | 3 | 9 | 0 | 0 | 0 | 3 | 0 | 15 |
| ICUS | 9 | 2 | 20 | 0 | 0 | 4 | 27 | 62 |
| AML with <30% blasts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other AML | 4 | 0 | 0 | 10 | 32 | 0 | 0 | 46 |
| Other malignancy | 3 | 8 | 0 | 0 | 2 | 26 | 10 | 49 |
| Other | 54 | 14 | 21 | 2 | 3 | 53 | 335 | 482 |
| Total | 266 | 45 | 49 | 15 | 38 | 93 | 412 | 918 |
| Agreement rate | 73% (193/266) | 20% (9/45) | 41% (20/49) | 0% (0/15) | 84% (32/38) | 28% (26/93) | 81% (335/412) | 67% (615/918) |
| κ (95% CI) | 0.54 (0.49-0.59) | |||||||
| Original local diagnosis . | Final study diagnosis . | |||||||
|---|---|---|---|---|---|---|---|---|
| MDS . | MDS/MPN overlap . | ICUS . | AML with <30% blasts∗ . | Other AML . | Other malignancy . | Other . | Total . | |
| MDS | 193 | 12 | 8 | 3 | 1 | 7 | 40 | 264 |
| MDS/MPN overlap | 3 | 9 | 0 | 0 | 0 | 3 | 0 | 15 |
| ICUS | 9 | 2 | 20 | 0 | 0 | 4 | 27 | 62 |
| AML with <30% blasts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other AML | 4 | 0 | 0 | 10 | 32 | 0 | 0 | 46 |
| Other malignancy | 3 | 8 | 0 | 0 | 2 | 26 | 10 | 49 |
| Other | 54 | 14 | 21 | 2 | 3 | 53 | 335 | 482 |
| Total | 266 | 45 | 49 | 15 | 38 | 93 | 412 | 918 |
| Agreement rate | 73% (193/266) | 20% (9/45) | 41% (20/49) | 0% (0/15) | 84% (32/38) | 28% (26/93) | 81% (335/412) | 67% (615/918) |
| κ (95% CI) | 0.54 (0.49-0.59) | |||||||
The number of participants assigned to each disease group crossclassified by assignment source is reported in this table, along with the agreement rates and κ statistics. Denominator in percentage represents the number participants reviewed that were assigned to disease group by final study diagnosis.
AML with <30% blasts without core binding factor or acute promyelocytic leukemia.